GTP-Binding Mutants of Rab1 and Rab2 are Potent Inhibitors of Vesicular Transport from the Endoplasmic Reticulum to the Golgi Complex

Ellen J. T'tsdale*, Jeffrey R. Bourne**†, Roya Khosravi-Far‡, Channing J. Der‡ and W. E. Balch*

* Departments of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037; and ‡ La Jolla Cancer Research Foundation, La Jolla, California 92037

Abstract. We have examined the role of ras-related rab proteins in transport from the ER to the Golgi complex in vivo using a vaccinia recombinant T7 RNA polymerase virus to express site-directed rab mutants. These mutations are within highly conserved domains involved in guanine nucleotide binding and hydrolysis found in ras and all members of the ras superfamily. Substitutions in the GTP-binding domains of rabla and rablb (equivalent to the ras 17N and 116I mutants) resulted in proteins which were potent trans dominant inhibitors of vesicular stomatitis virus glycoprotein (VSV-G protein) transport between the ER and cis Golgi complex. Immunofluorescence analysis indicated that expression of rablblu prevented delivery of VSV-G protein to the Golgi stack, which resulted in VSV-G protein accumulation in pre-Golgi punctate structures. Mutants in guanine nucleotide exchange or hydrolysis of the rab2 protein were also strong trans dominant transport inhibitors. Analogous mutations in rab3a, rab5, rab6, and H-ras did not inhibit processing of VSV-G to the complex, sialic acid containing form diagnostic of transport to the trans Golgi compartment. We suggest that at least three members of the rab family (rabla, rablb, and rab2) use GTP hydrolysis to regulate components of the transport machinery involved in vesicle traffic between early compartments of the secretory pathway.

Members of the rab family of ras-related small GTP-binding proteins are associated with subcellular compartments in both the endocytic and exocytic pathways (reviewed in Balch, 1990; Goud and McCaffrey, 1991). These proteins are likely to be key regulatory components of protein complexes catalyzing the fission and fusion of transport vesicles between distinct subcellular compartments. In support of their proposed function, the ras-related yeast GTP-binding proteins YPT1 and SEC4 have been shown to be required for transport between the ER and the Golgi complex (reviewed in Hicke and Schekman, 1990; Schmit et al., 1988; Segev et al., 1988; Bacon et al., 1989; Baker et al., 1990; Kaiser and Schekman, 1990), and from the Golgi complex to the cell surface (Salminen and Novick, 1987; Goud et al., 1988; Walworth et al., 1989), respectively. In addition, in vitro assays which efficiently reconstitute ER to Golgi (Beckers et al., 1987) and intra-Golgi transport (reviewed in Waters et al., 1991; Rothman and Orci, 1992) are sensitive to the nonhydrolyzable analog of GTP, GTPγS (Melencon et al., 1987; Beckers and Balch, 1989).

Within the mammalian rab gene family, rabla and rablb share 70–80% identity to YPT1 (Valencia et al., 1991). In fact, mouse rabla can complement mutant yeast which lack YPT1 (Haubruck et al., 1989). Although genetic studies in yeast have shown that the YPT1 gene is required in vesicular transport, there is limited data which demonstrates a similar role of the mammalian rab homologue in membrane traffic. We have shown that a peptide homologous to the putative effector domain of the rabla protein inhibits ER to Golgi transport, presumably by competition for a downstream effector molecule(s) required for vesicle fusion (Plutner et al., 1990). In addition, a neutralizing monoclonal antibody specific for the rablb protein inhibits transport from the ER to the Golgi complex in vitro (Plutner et al., 1991).

All members of the ras superfamily contain highly conserved domains required for guanine nucleotide binding, GTP/GDP exchange, and GTP hydrolysis (Bourne et al., 1990; Bourne et al., 1991). These domains interact with proteins which stimulate guanine nucleotide dissociation (GDS), inhibit GDP exchange (GDI), and promote GTP hydrolysis (GAP) (reviewed in Hall, 1990; Haubruck and McCormick, 1991; Wittinghofer and Pai, 1991; Takai et al., 1992). A host of amino acid substitutions (>100) made in the ras GTP-binding and effector domains have led to the identification of several activation and inhibitory mutations (Barbacid, 1987). Similar substitutions in the SEC4 and YPT1 proteins result in trans dominant negative phenotypes.
which inhibit vesicular transport (Walworth et al., 1989; Becker et al., 1991).

Using the mutational analysis performed on ras as a model, we have explored the role of rab proteins in ER to Golgi complex transport in mammalian cells using site-directed mutagenesis and a vaccinia based transient expression system. We report that rabla and rablb mutants with altered GDP/GTP binding properties behave as potent trans dominant inhibitors of ER to Golgi complex transport in vivo. In addition, we provide evidence that mutations in the dominant inhibitors of ER to Golgi intermediate compartment (Chavrier et al., 1990a), results in proteins which act as trans dominant inhibitors in vesicular traffic. Our results suggest that at least three members of the rab family (rabla, lb, and 2) are critical for regulating the biochemical machinery involved in vesicle fission and fusion between early compartments of the secretory pathway.

Materials and Methods

Cell Culture and Generation of Mutant Constructs

HeLa cells were cultured in DME (Gibco BRL, Grand Island, NY) supplemented with 10% FBS and penicillin-streptomycin in a 5% humidified CO2 incubator. Rab expression constructs were generated from canine rabla (Chavrier et al., 1990a), rat rabla (Touchot et al., 1987), and human rab2, rab3a, rab5, and rab6 (Zahraoui et al., 1989) cDNA sequences that have been generously provided by M. Zerial (EMBL, Heidelberg, Germany) and A. Tavitian (INSERM, Paris, France). All rab sequences were introduced into the Ndel and BamHI sites of the pET3a vector (Novagen, Madison, WI) for expression (Studier et al., 1990) from the T7 promoter as described previously (Khosravi-Far et al., 1991). To generate structural mutants of each rab protein (see Table 2), oligonucleotide-directed mutagenesis was done on M13 mpl8 vector constructs of each rab cDNA sequence using the Polymerase III Mutator protocol (Stratagene Corp., La Jolla, CA) or by TaqI polymerase chain reaction DNA amplification. All mutated rab sequences were verified by dyeoxy sequencing. The pET-rab constructs were introduced into E. coli strain BL21-DE3 (Novagen) for expression of recombinant rab protein and used for transfection experiments. The pAR-G (pET3a) plasmids encoding VSV-G and tO45 VSV-G were obtained from J. Rose (Yale University, New Haven, CT) and C. Machamer (Johns Hopkins University, Baltimore, MD).

Transfection Procedure

HeLa cells were plated (5 × 10^5/25 mm dish) on the day before transfection. The cells were first washed twice with DME, then infected with a vaccinia T7 RNA polymerase recombinant virus (vTF7-3) (Fuerst et al., 1986), at a multiplicity of 10 PFU/cell for 30 min with intermittent rocking at 37°C. The inoculum was removed and the cells cotransfected with 5 μg pET-rab plasmid DNA encoding for a mutated rab protein as described above, and 5 μg of plasmid encoding for VSV-G protein (pAR-G) that had been premixed for 15 min at room temperature in 1 ml DME and 15 μl of the transfection reagent (TransfectACE [Gibco-BRL]) as outlined by Rose (Rose et al., 1991). 3 h post-transfection, an equal volume of DME/10% FBS was added to the cells and incubated for an additional 3 h to allow synthesis of VSV-G protein and the mutant rab protein. After the transfection period, the media was removed and the cells incubated for 15 min in methionine-free MEM (Gibco-B, Ga.) biotransformed labeled for 10 μCi [35S]-methionine (spec. act. 1192 Ci/mmol, ICN Biomedicals, Inc., Irvine, CA), then chased for 1 h in DME/10% FBS. The chase was terminated by the addition of lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF) (Sigma Chemical Co., St. Louis, MO) and the lysate preclarified for 30 min. with 50 μl Pansorbin (Pansorbin, Inc., San Diego, CA). The soluble fraction was incubated overnight at 4°C with a monoclonal antibody to VSV-G (clone 8G5) and Pansorbin. Immune precipitates were washed three times with 10 mM Tris, pH 6.8/1% SDS, boiled, then centrifuged. To the supernatant was added 30 μl of 0.2 M citrate, pH 5.5 and 5 μl of endoglycosidase H (endo H) (1 U/ml, Boehringer Mannheim Corp., Indianapolis, IN) and the sample digested overnight at 37°C. Samples were analyzed by SDS-PAGE on 7.5% gels according to the method of Laemmli (Laemmli, 1970). The gel was soaked in 1 M salicylate/30% methanol for 30 min, dried, then exposed to XAR-5 film (Eastman Kodak Corp., Rochester, NY) at -80°C. Quantitation of the VSV-G protein was accomplished using densitometry as described previously (Beckers et al., 1987; Beckers and Balch, 1989; Schwanger et al., 1990).

Transport Kinetics and Protein Expression of rabla/b

HeLa cells (3 × 10^5/10 cm dish) were infected/transfected at a multiplicity of 10 PFU/cell and 30 μg of mutant rab and 30 μg pAR-G, as described above. 2 h post-transfection, the media was removed and saved, and the cells detached from the culture dish with PBS/50 mM EDTA. The cells were washed one time with DME then replated at equal number in 35-mm dishes with transfection media from the parental dish and equal volume of DME/10% FBS. This would allow a common pool of transfected cells to be analyzed. At 3, 4, 5 and 6 h post-transfection cells were biotransformed labeled for 10 min and chased for 60 min in complete media, as outlined above.

To determine the level of expression of the rab protein, a comparable number of cells at each time point were detached from the dish with PBS/EDTA and washed one time with 10/18 (10 mM KOAc/18 mM HEPES [pH 7.2]). The cells were resuspended in 10/18 containing protease inhibitors (5 μg/ml leupeptin, 10 μg/ml aprotinin, 1 μg/ml TLCK, 1 μg/ml chymotrypsin, 0.1 μM pepstatin), swollen on ice for 10 min., then homogenized by 10 passes through a 23 gauge needle after which the concentration was adjusted to 25 mM KOAc/125 mM Heps. The nuclei were removed by centrifugation for 5 min. at 3,000 RPM and the post-nuclear supernatant centrifuged at 30 PSI for 30 min. at 4°C in a Beckman Airfuge. The supernatant was removed and the membrane pellet resuspended in 25/125. Protein determinations were made by the Micro BCA Protein Assay Reagent (Pierce Chem. Co., Rockford, IL). Aliquots of the supernatant and membrane fractions (100 μg total protein) were separated by SDS-PAGE on a 12% gel and transferred to nitrocellulose (Schleicher and Schuell, Keene, NH) in 25 mM Tris pH 8.3, 192 mM glycine, 20% methanol. The membrane was blocked in 5% nonfat dry milk, 0.05% Tween-20 in TBS. Detection of rabla was with the polyclonal antibody p68 (Pluntern et al., 1990) followed by 1 μl/25 μl Protein A (spec. act. 85 μCi/μg. ICN). Standard curve was generated from purified recombinant rab protein.

Western Analysis of Wild Type and Mutant Rab Proteins

HeLa cells (5 × 10^5/35 mm dish) were infected/transfected, as outlined above. 6 h post-transfection, the cells were detached from the culture dish with PBS/EDTA, washed two times with PBS, then lysed in 10% TCA for 2 h on ice. TCA-precipitated material from the cells was washed one time with acetone and dissolved in 100 μl of sample buffer (0.1% SDS, 0.5 M Tris-HCl, pH 6.8, 10% glycerol, 5% β-mercaptoethanol, and 0.1% bromophenol blue). Samples were separated by SDS-PAGE using 12% gels and transferred to nitrocellulose as described above. After blocking, the membrane was incubated with the appropriate anti-rab antibody, then incubated with an alkaline phosphatase-conjugated secondary antibody (Pierce Chemical Co.) and developed with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (Pierce Chemical Co.). HeLa cell (5 × 10^5) lysate of non-transfected cells was coanalyzed to determine the endogenous level of rab protein. Purified recombinant rab proteins were included as controls. Overexpression of rab proteins was detected by antibody reagents specific for rabla (m5C0b) (Pluntern et al., 1991), rab2a (W. E. Balch, unpublished data), rab5 (generously provided by M. Zerial, EMBL) and a polyclonal antibody which cross-reacts with rabla, lb, 3 and 6.

Indirect Immunofluorescence

HeLa cells (5 × 10^5) were plated on coverslips in 35-mm tissue culture dishes on the day before transfection. Cells were infected/co-transfected as above with 5 μg pET tO45-G, 5 μg pET rabla and/or 5 μg of pET rablb. Cells were incubated at 40°C for 4 h followed by incubation at 32°C for 2 h. To terminate transport, the cells were transferred to ice, fixed with 3% paraformaldehyde/PBS for 20 min at room temperature. Fixation was quenched with 10 mM ammonium chloride in PBS for 10 min then blocked in PBS/5% normal goat serum (NGS) for 10 min at room temperature. To detect intracellular VSV-G, cells were permeabilized with 0.05% saponin in PBS/NGS for 10 min, washed with PBS, then incubated for 30 min with a monoclonal antibody specific for the VSV-G protein cytoplasmatic tail.
Results

A Transient Expression System to Study rab Protein Function In Vivo

To study the in vivo consequences of mutated forms of the rab proteins on vesicular traffic, we employed a transient expression system in which HeLa cells are first infected with vaccinia T7 RNA polymerase recombinant virus (vTF7-3) then cotransfected with a mutant rab plasmid DNA and a plasmid encoding for vesicular stomatitis virus glycoprotein (VSV-G) (pAR-G) which serves as the reporter molecule (Fuerst et al., 1986; Moss, 1989). VSV-G protein is a type I integral membrane protein which acquires two N-linked oligosaccharides during cotranslational insertion into the ER. Transport of VSV-G protein from the ER to the cis/medial Golgi compartments results in processing of the high mannose (mano) endoglycosidase H sensitive (endo Hs) oligosaccharides found in the ER to the complex, endo H resistant (endo Hr) forms present in the Golgi stack and on the plasma membrane due to trimming by Golgi associated mannosidases and glycosyl transferases. Appearance of the various oligosaccharide processing intermediates can be used to follow the transport of VSV-G through the cis, medial, and trans Golgi compartments. These intermediate forms of VSV-G can be distinguished by their unique mobilities after SDS-PAGE (Schwaninger et al., 1991).

To establish conditions to study transport, Hela cells infected with vTF7-3 were transfected with the VSV-G protein encoding plasmid at 60 min intervals, biosynthetically radiolabeled for 10 min, then chased for 1 h in the absence of radioactive label. Immunoprecipitated G protein was first detected 3 h post-transfection and continued to increase in concentration in a linear fashion with time (data not shown). We selected the 4–6 h post-transfection period to study transport because both rab and VSV-G proteins were expressed at significant levels without adversely affecting the secretory pathway. The rate of transport of VSV-G from the ER to the Golgi complex in vaccinia infected/transfected HeLa cells. Vaccinia infection and pAR-G (a plasmid encoding the VSV-G protein) transfection were performed as described in Materials and Methods. VSV-G protein was immunoprecipitated and incubated in the absence or presence of endoglycosidase H (endo H) as described in Materials and Methods. The endoglycosidase sensitive (endo Hs, lower band) forms and endoglycosidase H resistant (endo Hr, upper band) form were separated by SDS-PAGE. The fraction (%) of VSV-G protein transported to the endo H resistant form (lower panel) was quantitated as described in Materials and Methods. VSV-G protein is converted to the endo Hs form with a half-time of 30 min.

Figure 1. Kinetics of transport of VSV-G from the ER to the Golgi complex in vaccinia infected/transfected HeLa cells. Vaccinia infection and pAR-G (a plasmid encoding the VSV-G protein) transfection were performed as described in Materials and Methods. VSV-G protein was immunoprecipitated and incubated in the absence or presence of endoglycosidase H (endo H) as described in Materials and Methods. The endoglycosidase sensitive (endo Hs, lower band) forms and endoglycosidase H resistant (endo Hr, upper band) form were separated by SDS-PAGE. The fraction (%) of VSV-G protein transported to the endo H resistant form (lower panel) was quantitated as described in Materials and Methods. VSV-G protein is converted to the endo Hs form with a half-time of 30 min.

Mutations in GTP-Binding Domains of rab1 are Trans Dominant Inhibitors of ER to Golgi Transport

To identify rab proteins essential for vesicular transport between the ER and the Golgi complex, we performed site-directed mutagenesis within domains involved in guanine nucleotide interactions. Ras and rab proteins contain four highly conserved GTP-binding domains (Bourne et al., 1991; Valencia et al., 1991). Mutational and structural analysis of the ras protein have determined essential amino acid residues in these domains for binding and hydrolysis of GTP (reviewed in Barbacid, 1987; Valencia et al., 1991) (Table 1). Amino acid substitutions at specific sites in the guanine nucleotide binding domains of ras alter guanine nucleotide binding affinity for GDP and GTP.
Publishes November 15, 1992

Mutant substitution
ras transport

rablb, Asp(GAC) - Asn(AAC) 39N -

rablb41M, He(AT_T) - Met(ATG) 36M -/+ 

rablb4Oa, Thr(ACC) - Ala(GCT) 35A - 

rablb22N, Ser(TCA) - Asn(AAC) 17N +

rab61 Asn(AAT) - lle(A_TT) 116I - 

 Аналогous ras mutant protein.

min, then chased for 1 h in nonradioactive medium to pro-

Figure 2. Mutations in GTP-binding domains of rabla and rablb are trans dominant inhibitors of transport from the ER to the Golgi complex. Vaccinia infection and cotransfection protocols with pAR-G and mutant (pET) plasmids were as described in Materials and Methods. Briefly, 5 h post-transfection cells were labeled with trans (35S) for 10 min and chased for 60 min in the absence of radiolabel. VSV-G protein was immunoprecipitated and digested in the absence (-) or presence (+) of endo H, and the endo H sensitive (S) or resistant (R) forms analyzed by SDS-PAGE as described in Materials and Methods. Ri is a processing intermediate with one of the two oligosaccharide chains processed to the endo H resistant form (Schwaninger et al., 1991). R2 is the form of VSV-G containing two endo H resistant oligosaccharides fully processed and containing sialic acid. Transport of VSV-G protein from the ER to the Golgi complex is totally inhibited in cells over-expressing rablb121t, and rabla121t, and rablb22N.

As shown in Fig. 2, overexpression of rablb121t (≈10-fold)
resulted in a complete block of VSV-G protein transport (Fig. 2, lane l). No processing of VSV-G protein to endo H$_a$ forms was observed after the 60 min chase period compared to the control in which 75% of the VSV-G protein was processed to the endo H resistant form (Fig. 2, compare lanes b and l). VSV-G neither accumulated in the Man$_5$ endoglycosidase D sensitive form (data not shown), a processing reaction diagnostic of protein transport to the cis Golgi compartment in the mutant CHO cell line clone 15B (Beckers et al., 1987), nor in an early endo H$_a$ processing intermediate observed in the control (R$_i$ in Fig. 2, lanes b or d) diagnostic of transport from the ER to the cis Golgi compartment in wild-type CHO cells (Schwaninger et al., 1991). Identical results were obtained for rabla$_{2121}$ (95% identity with rabb) (Fig. 2, lane j). As expected, recombinant rabla$_{2121}$ (data not shown) or rablb$_{2121}$ did not bind detectable levels of GTP (<0.1%) compared to the wild-type proteins measured in solution or by Western blotting (Fig. 3, lanes a and e). In contrast, VSV-G protein was efficiently (>85%) transported and processed to the fully sialylated, complex form (R$_i$ in Fig. 2, lane d) in the presence of overexpressed (~10-fold) wild-type rablb or wild-type rabla (data not shown). We have been unable to detect any statistically significant change in the extent or rate of processing of VSV-G to endo H$_a$ forms in cells overexpressing (10-fold) wild-type rablb or 1b (data not shown), suggesting that the endogenous rabl protein is not rate limiting for transport of VSV-G protein from the ER to the terminal compartments of the Golgi complex.

To provide evidence that expression of the rablb$_{2121}$ protein imposes a transport block between the ER and the Golgi stack, we analyzed the distribution of VSV-G in the presence of rablb$_{2121}$ by indirect immunofluorescence. For this purpose, Hela cells were transfected with a plasmid (pAR-tsO45-G protein) expressing a temperature-sensitive form of VSV-G which misfolds at the restrictive temperature (39.5°C) and fails to be exported from the ER (Lafay, 1974; Balch et al., 1986) (Fig. 4, A [VSV-G] and B [Golgi complex]). TsO45-VSV-G is rapidly mobilized to the Golgi membranes when shifted to the permissive temperature (32°C) (Fig. 4, C [VSV-G] and D [Golgi complex]). When cells cotransfected with pAR-tsO45-G and wild-type rablb and were held at the restrictive temperature for 4 h followed by a 90 min chase at the permissive temperature, VSV-G protein was found to be efficiently transported to the Golgi complex (Fig. 4, E, E′ [VSV-G] and F, F′ [Golgi complex]). In contrast, expression of rablb$_{2121}$ resulted in the inability of VSV-G to enter the Golgi stack. The tsO45-G protein was partially transported to punctate structures scattered throughout the cytoplasm (Fig. 4, G, G′ [VSV-G] and H, H′ [Golgi complex]), similar to the distribution of pre-Golgi intermediates in BHK cells (Saraste, 1984; Saraste et al., 1991). Furthermore, cells expressing tsO45 VSV-G and rablb$_{2121}$ failed to transport VSV-G protein to the surface (Fig. 5, B) indicative of a block in transport.

The striking inhibition of protein transport produced by expression of rablb$_{2121}$ prompted us to examine the threshold of this mutated protein required to inhibit vesicular traffic. Cells cotransfected with the VSV-G protein encoding plasmid and pET rablb$_{2121}$ were radiolabeled at 3, 4, 5, and 6 h post-transfection for 10 min, chased for 1 h, then transport assessed as described above. In addition, the level of expression and distribution of rablb between membrane and cytosol was quantitated by Western blotting (Fig. 6). The endogenous pool of rablb in Hela cells is distributed between membrane-associated and soluble forms (Fig. 6, B). Expression of rablb$_{2121}$ after a 3 h post-transfection period resulted in ~2 fold increase in the total rab pool (Fig. 5, B). Even at this level of expression of the mutant protein, VSV-G protein transport to the Golgi complex was reduced by ~25% (Fig. 5, A). From 4 to 6 h post-transfection, a 5- to 10-fold increase in rablb$_{2121}$ was observed with rablb$_{2121}$ now being detected increasingly in the membrane fraction (Fig. 3, B). At 6 h post-transfection transport was inhibited >80% (Fig. 5, A). In general, overexpression of rablb$_{2121}$ in the range of four to eightfold results in the total arrest of VSV-G protein transport and processing to the endo H$_a$ form as early as 3–4 h post-transfection. We have been unable to reverse inhibition by cotransfection with pET wild-type rablb suggesting that the rablb$_{2121}$ mutant irreversibly inhibits transport (data not shown).
F/gum 4. Rablb inhibits transport to the Golgi complex. Vaccinia infected cells (see Materials and Methods) were transfected with rablb or rablbmt cDNA, and a plasmid expressing the temperature-sensitive mutant form of VSV-G protein (pAR-tsO45-G) for 4 h at 39.5°C to retain tsO45 VSV-G in the ER. 4 h post-transfection, cells were shifted to the permissive temperature (32°C) and incubated for 2 h. Cells were fixed, permeabilized, and the distribution of tsO45 and VSV-G protein (A, C, E, E', G, G') and Golgi membranes (B, D, F, F', H, H') viewed by immunofluorescence microscopy as described in the Materials and Methods. (A, B) Distribution of tsO45 VSV-G (A) or Golgi membranes (B) after 6 h continuous incubation at 39.5°C. (C, D) Distribution of tsO45 VSV-G (C) or Golgi membranes (D) after incubation for 2 h at 32°C. (E, F) Distribution of tsO45 VSV-G (E, E') or Golgi membranes (F, F') after incubation for 2 h at 32°C in the presence of rablb protein. (G, H) Distribution of tsO45 VSV-G (G, G') or Golgi membranes (H, H') after incubation for 2 h at 32°C in the presence of rablbmt protein.

To further characterize the role of GTP-binding in the regulation of rabl function in ER to Golgi traffic, mutations were generated in two domains involved in either interaction with the phosphates or the guanine ring (Table 1). Rablb22N (Table 2) is equivalent to the rasN21T mutation which exhibits a 20-fold reduced affinity for GTP but not GDP. It is thought that rasN21T is locked in the GDP-bound form and to be associated constitutively with a ras guanine nucleotide dissociation stimulator (GDS) (Feig and Cooper, 1988). This mutant is a potent inhibitor of mammalian cell proliferation and believed to antagonize normal ras function by competition for GDS. As shown in Fig. 2 (lane f), expression of rablb22N (>10-fold) above the endogenous pool of rablb (data not shown) potently inhibited transport resulting in <2% of VSV-G processed to the endo HR forms. In contrast, overexpression of rablb67L (Table 2), which in ras (ras61L) eliminates the intrinsic and GAP-stimulated GTPase activities (Haubruck and McCormick, 1991), did not inhibit transport (Fig. 2, lane h, 85% endo HR) when expressed >10-fold over the endogenous wild type protein based on Western blotting (data not shown). The equivalent mutation in the SEC4p (SEC479L) does not inhibit transport from the
Figure 6. Relationship between rablb12u expression and inhibition of VSV-G transport from the ER to the Golgi complex. Infection/transfection conditions and analyses were as described in the legend of Fig. 3, and in Materials and Methods. (A) Extent of inhibition of VSV-G protein transport by rablb12u at 3, 4, 5, or 6 h post-transfection. (B) The level of expression of mutant rablb12u protein assessed by Western blotting after 3, 4, 5, or 6 h post-infection/transfection. Cytosolic fraction (C) and membrane fraction (M) were prepared as outlined in Materials and Methods. The control lane (ctl) shows the level of endogenous rablb. (C) The standard curve for rablb concentration was generated using purified recombinant rablb.

Figure 5. VSV-G protein is not delivered to the cell surface in HeLa cells expressing rablb12u. Vaccinia infected cells (see Materials and Methods) were transfected with a plasmid expressing the temperature-sensitive mutant form of VSV-G protein (pAR-tsO45-G) in the absence (A) or presence (B) of the plasmid expressing rablb12u for 4 h at 39.5°C. After 4 h, cells were shifted to the permissive temperature (32°C) and incubated for 2 h. Cells were fixed and surface expression of tsO45 VSV-G protein determined by indirect immunofluorescence using an antibody specific for the extracellular domain of VSV-G as described in Materials and Methods.
Golgi to the cell surface in yeast (Walworth et al., 1989). As expected, rablbnL did not bind GTP after Western blotting whereas rablb243 GTP-binding was normal (Fig. 3, compare lanes b and d).

**RablE Lacking the Carboxy-Terminal CC Motif Is a Trans Dominant Inhibitor of Transport**

Prenylation of the carboxy-terminal cysteine residues of small GTP-binding proteins is required for membrane association and function (reviewed in Der and Cox, 1991) (Table 1). We have previously demonstrated that the carboxy-terminal CC residues of rablb are post-translationally modified by a geranylgeranyl isoprenoid (Khosravi-Far et al., 1991). To assess the importance of this modification in rablb function, truncation (ΔCC) mutants were generated from the wild-type rablb and mutant rablbΔ243 proteins. As shown in Fig. 7, deletion of the terminal CC residues from the wild-type protein had no effect on transport. VSV-G protein was efficiently processed to the endo Hs form (Fig. 7, lane d, 65% endo Hs). RablbΔCC bound GTP at levels comparable to the wild-type protein (not shown). In contrast, and to our surprise, the rablbΔ243, ΔCC mutant inhibited ER to Golgi transport as efficiently as the nontruncated mutant (Fig. 6, lane f, <1% endo Hs) suggesting that a non-prenylated form of the mutant can effectively interfere with some aspect of the transport machinery governing rablb function.

To determine whether additional sequence information in the carboxy-terminus of rablb was necessary to yield the trans dominant phenotype produced by the rablbΔ243 mutant, we replaced the COOH-terminal 35 amino acids of rablb with the carboxy-terminal 35 amino acids of rab5 to generate the hybrid construct rablb11-150/121/rab5151-189 (Table 2). The carboxy-terminus of rab5 has been suggested to encode key information dictating the localization of the rab5 protein to an early endosome compartment (Chavrier et al., 1991). This mutant chimera binds GTP indicating that it folds properly to form a native structure (data not shown). In contrast to rablbΔ243, ΔCC, overexpression (∼10-fold) of the hybrid (data not shown) had no effect on VSV-G transport (Fig. 7).

**Rabl Effector Domain Mutations**

Mutations in amino acids 32–40 of ras (the effector domain [Table 1]) do not, for the most part, alter the intrinsic properties of ras yet abolish transforming activity of the oncogenic forms (Hall, 1990; Haubruck and McCormick, 1991). Mutations in this region which destroy ras transforming activity typically eliminate the ability of GAP to bind efficiently to ras. Although the ras and rab effector domains are highly divergent, the 35T residue within the effector domain is invariant among all ras and ras-related proteins (Table 1) (Velencia et al., 1991; Wittinghofer and Pai, 1991). Substitution of 35T with A results in loss of ras transforming activity and prevents GAP stimulation of GTPase activity.

To determine whether mutations in the rablb effector domain would inhibit ER to Golgi transport, three different mutants were generated (Table 2): rablbΔ40A, rablbΔ5M and rablbΔM. In the case of rablbΔ5M GTP-binding is comparable to the wild-type protein (Fig. 3, lane c). RablbΔM and rablbΔM are identical to YPTIp effector domain mutants recently reported to yield secretory defects in ER to Golgi transport in yeast (Becker et al., 1991). As shown in Fig. 8, we have detected weak, yet reproducible inhibition with rablbΔM (Fig. 8, 50% endo Hs). This mutation in YPTip yields the strongest trans dominant phenotype (Becker et al., 1991). In contrast, no inhibition was observed by overexpression of the rablbΔ40A or rablbΔM (Fig. 8). Because the 44N substitution in YPTi results in a temperature sensitive-phenotype (Becker et al., 1991) we tested whether a block in transport could be detected at an elevated temperature (39.5°C) in the presence of the rablbΔM protein. As before, no inhibitory phenotype was detected (data not shown). In all cases, expression levels were ∼10-fold that of the endogenous pool (data not shown). These results are compatible with the observation that effector domain mutations in mammalian ras are generally neither trans dominant nor growth inhibitory (Hall, 1990; Haubruck and McCormick, 1991).

**Mutations in the GTP-Binding Domains of rab2 are Trans Dominant Inhibitors of ER to Golgi Transport**

The rab2 protein, which is highly divergent from rablb (<40% identity), has been immunolocalized to the tubular-vesicular compartments believed to function in ER to Golgi transport from the ER to the Golgi complex. Infection/transfection conditions and analyses were as described in Materials and Methods. Overexpression of the double mutant, rablbΔ243, ΔCC, resulted in a complete inhibition of VSV-G transport.

**Figure 7.** The effect of carboxy-terminal mutations in rablb on VSV-G protein transport from the ER to the Golgi complex. Infection/transfection conditions and analyses were as described in Materials and Methods. Overexpression of the double mutant, rablbΔ243, ΔCC, resulted in a complete inhibition of VSV-G transport.

**Figure 8.** Effect of VSV-G transport in cells expressing mutations in the effector domain of rablb. Infection/transfection conditions and analyses were as described in Materials and Methods.
transport (Chavrier et al., 1990a). However, no genetic or biochemical evidence is currently available which demonstrates its involvement in vesicular traffic.

To determine if rab2 functions in ER to Golgi transport, rab2 mutants were generated based on our observations for the rablb constructs (Table 2). We first tested rab2,9~ (equivalent to rablb,m~), a mutant which was likely to yield a trans dominant inhibitory phenotype. Rab2Hg~ failed to bind GTP on Western blots (Fig. 3, lane j) and strongly inhibited protein transport from the ER to the Golgi complex (Fig. 9, <5% endo H resistant). In contrast, expression of rab2 wild-type protein neither stimulated nor inhibited the transport of VSV-G protein to the Golgi (Fig. 9, 65% endo H R). Three additional mutants were generated (Table 2): 1) rab220N, analogous to the rasl7N mutation, 2) rab238A, an effector domain mutation, and 3) rab265L corresponding to the oncogenic ras61L mutation. We observed (Fig. 2, lane f) only a partial inhibition in membrane traffic by rab220N (Fig. 9, 45% endo H), although it was expressed as efficiently as rabl proteins (~10-fold) and did not bind GTP after Western blotting (Fig. 3, lane g). Surprisingly, the rab265L mutant was a potent inhibitor of transport (Fig. 9, <1% endo H) and bound GTP at levels comparable to wild-type (Fig. 3, lane i). The equivalent rablb65L had no effect on transport (Fig. 2, lane h). We have also consistently detected a weak, but reproducible inhibitory phenotype with the rab265L effector domain mutation (Fig. 9, 40% endo H). As expected, GTP-binding by this mutant was comparable to wild type (Fig. 3, lanes f and h). The combined results suggest not only that rab2 is critical for ER to Golgi traffic, but the biochemical interactions facilitating rab2 function differ from those for rablb.

Overexpression of rab3a, rab5, rab6 Wild Type and GTP-Binding NKXD Mutant Proteins Have No Effect on Vesicular Traffic Between the ER and the Golgi Complex

To show that VSV-G protein transport inhibition between the ER and Golgi compartments is specific to those rab mutants described above, we expressed rab proteins which have been reported to participate in other steps of vesicular transport. To this end, we introduced the equivalent ras186 mutation in rab3a, rab5, and rab6. Rab3 is involved in regulated exocytosis in endocrine, exocrine, and neural tissues and has been localized to exocytic vesicles (Darchen et al., 1990; Fisher von Mollard et al., 1990). Rab5 has been localized to endosomal compartments and is involved in early endosome fusion in vitro (Chavrier et al., 1991; Gorvel et al., 1991). The rab6 protein has been localized to the medial-trans compartments of the Golgi complex (Goud et al., 1990). As indicated in Fig. 10, overexpression (~10-fold) of the wild-type or mutant rab3a,135L, wild-type or mutant rab5,133L, or H-ras,161L had no statistically significant inhibitory or stimulatory effect on processing of VSV-G protein to the endo H form. In addition, we have been unable to detect any inhibitory effect of overexpression of rab6,156 on processing of VSV-G to the terminally sialylated, complex form (Fig. 11). Given that sialyltransferase is a late-processing enzyme predominantly found in the trans Golgi compartment and trans Golgi network, these results suggest that rab6 is not essential for transport between cis, medial or trans Golgi compartments. Similarly, the inability of H-ras, rab3a, rab5 and rab6 NKXD mutant proteins to inhibit VSV-G transport between the ER and the Golgi complex indicates that these proteins do not interact with the biochemical machinery governing rabl or rab2 function.

Discussion

Disruption of ER to Golgi Transport by rabl and rab2 Mutations Affecting GTP Binding and Hydrolysis

Mutational analysis of ras and ras-related proteins has re-
revealed critical residues within conserved domains involved in GTP binding, exchange and hydrolysis required for function. We have used the structure/function data reported for the ras protein as our prototype to map functional domains in the rab proteins necessary for vesicular traffic from the ER to the Golgi complex.

Since guanine nucleotide binding regulates the biological activity of ras, we generated the N to I substitution in the consensus NKXD (ras residues 116-119) GTP-binding domain present in all ras-related proteins. While this substitution activates ras transforming potential (Der et al., 1988), analogous mutants of YPT1 (Schmitt et al., 1986; Schmitt et al., 1988), SEC4 (Walworth et al., 1989), and rab5 (Gorvel et al., 1991) exhibit trans dominant inhibitory phenotypes. To identify trans dominant inhibitors of ER to Golgi transport we made use of the T7 RNA polymerase produced by recombinant vaccinia virus to direct high level transient expression of rab proteins and VSV-G protein. In this system, rab1b121 was a potent inhibitor of VSV-G protein transport from the ER to the Golgi complex based on the observation that the two N-linked oligosaccharides of VSV-G protein failed to be processed to early post-ER, cis Golgi forms (Schwaninger et al., 1991). Indirect immunofluorescence studies confirmed the biochemical results: VSV-G failed to enter the Golgi stack and was not detected on the cell surface. Thus, it is unlikely that the inability to trim VSV-G protein oligosaccharides to endo Hα forms is due to a processing defect per se or an “end-run” around the Golgi complex. The punctate intermediates in which VSV-G accumulated in the presence of the rab1b121 mutant was strikingly similar to the distribution of a putative pre-Golgi intermediate compartment postulated to be involved in ER to Golgi transport (Saraste and Kuijman, 1984; Saraste and Svensson, 1991; Schweizer et al., 1988). Although the data presented here does not directly distinguish between accumulation of VSV-G protein in a terminal export site (budding vesicle) associated with the ER network or accumulation in a downstream post-ER, pre-Golgi transport intermediate, our preliminary analysis using immunoelectron microscopy strongly suggests the latter interpretation (W. E. Balch and M. G. Farquhar, unpublished data). The identification of the intracellular compartment where transport is blocked by other trans dominant negative mutations is currently under investigation.

Overexpression of rabla1211 yielded an identical biochemical phenotype to that observed for rab1b121. Rabla and rablb are 95% identical, with the major differences being found in both conservative and nonconservative substitutions in the carboxyl-terminus (Zahraoui et al., 1989). Given the ability of mouse rabla to substitute for YPT1p in yeast (Haubruck et al., 1989), our results suggest that rabla and rablb proteins may be functionally interchangeable in mammalian cells. Redundancy in expression of highly-related iso-types is not unusual among members of the ras-superfamily of small GTP-binding proteins (Valencia et al., 1991).

Biochemical and mutational analyses of rab-related proteins found in the exocytic pathway of yeast (Schmitt et al., 1988; Bacon et al., 1989; Walworth et al., 1989; Baker et al., 1990; Kaiser and Schekman, 1990; Becker et al., 1991; Rexach and Schekman, 1991) supports our interpretation that rabla is essential for ER to Golgi transport. Specifically, YPT11211 and SEC41331 do not bind GTP and are dominant-lethal mutants (Salminen and Novick, 1987; Walworth et al., 1989). Although the morphological and biochemical phenotype of YPT11211 in the secretory pathway of yeast has not been examined, temperature-sensitive mutants of SEC4 accumulate invertase and carboxypeptidase Y in the coreglycosylated pre-Golgi oligosaccharide forms, and accumulate ER and pre-Golgi transport vesicles in vivo and in vitro (Schmitt et al., 1988; Segev et al., 1988; Bacon et al., 1989; Walworth et al., 1989; Baker et al., 1990; Kaiser and Schekman, 1990; Becker et al., 1991). Likewise, SEC41331 leads to the accumulation of transport vesicles between the trans Golgi compartment and the cell surface (Walworth et al., 1989). These data support our biochemical observations and morphological studies suggesting that rab1b1211 expression results in the accumulation of VSV-G protein in pre-Golgi compartments. However, unlike the reversal of the dominant lethal phenotype observed by overexpression of wild-type protein on the negative effects of SEC41221 and YPT11211 in yeast (Schmitt et al., 1988; Walworth et al., 1989), overexpression of rablb wild type was unable to compete with rab1b1211. We suggest that rab1b1211 may inhibit transport by an irreversible binding to an effector molecule(s) required for rablb function.

The 116I (ras numbering) mutation in the NKXD domain of rab3a, rab5, rab6, and H-ras did not inhibit transport between the ER and Golgi membranes, consistent with their lack of activity in the early compartments of the secretory pathway. Although rab6 has been localized to medial/trans compartments of the Golgi complex (Goud and McCaffrey, 1991), overexpression of rab61261 failed to inhibit processing of VSV-G to the complex sialic acid containing structure. Transport between the medial and trans Golgi compartments is likely to involve vesicular carriers (Rothman, 1987). The inability of rab61211 to inhibit VSV-G transport suggests that rab6 does not regulate this step in the pathway. The combined results strengthen the general model that specific rab proteins participate in unique molecular interactions which regulate the function of different membrane-bound compartments in the endocytic and exocytic pathways. The analogous ras116 substitution in different rab proteins will likely serve as a general and sensitive tool to define the role of uncharacterized rab proteins in endomembrane function.

In addition to the requirement for rablb, we have provided the first evidence that rab2 is essential for transport from the ER to the Golgi complex. Our data supports the observation that rab2 is localized to pre-Golgi tubular-vesicular elements believed to be involved in ER to Golgi transport (Chavrier et al., 1990a; Saraste and Kuijman, 1984; Saraste and Svensson, 1991; Schweizer et al., 1988). The evolutionary divergence of rab2 from rablb (<40% identity [Valencia et al., 1991]) suggests that a distinct collection of upstream and downstream effector proteins regulating guanine nucleotide-binding, hydrolysis and/or membrane-association exists for the rab2 protein. To date, a rab2 homologue has not been detected in yeast. Whether the mammalian and yeast pathways differ in this respect is not known.

Mutations in a second domain involved in GTP-binding (GXXXXGKS/T) were examined (Table 1, ras numbering 10-17). The 17N substitution in ras is thought to result in formation of a GDP-complexed form (Feig and Cooper, 1988) due to the tight-binding of a ras specific GDS to this mutant protein. Because this protein is essential for normal ras func-
tion, cells expressing this mutant are growth inhibited. While the rablb2mt was a potent inhibitor of transport, the identical substitution in rab2 had a markedly reduced effect. We would propose that GDP/GTP exchange is critical for regulation of carrier vesicle function by rab1. Although GDI and GDS proteins have now been identified for a number of rab and rab-related small GTP-binding proteins (reviewed in Takai et al., 1992) their role in transport and other cellular functions remains to be elucidated.

We also examined the function of the highly conserved DTAGZEX domain (Table 1, ras numbering 57–63) which interacts with the phosphoryl group (Table 1). In the case of ras, this domain is critical for GTase activity (Hall, 1990) and insures specificity to ras-GAP (Maruta et al., 1991). Ras331 mutants have impaired intrinsic and GAP-stimulated GTase activities which favor formation of the active, GTP-complexed form and results in transformation (Der et al., 1986). Whereas rablb331 did not inhibit transport, rab2331 was a potent trans dominant inhibitor of VSV-G protein transport. The failure of rablb331 to arrest transport mirrors the observation that a similar mutation in SEC4 (SEC479L) has no effect on vesicular transport from the trans Golgi to the cell surface in yeast (Walworth et al., 1989). In contrast, the inhibitory phenotype observed for rab2331 agrees with results reported for ras, suggesting that the inability to hydrolyze GTP or enhanced GAP-binding contributes significantly to transport inhibition. Why rabl and rab2 differ in this respect is unknown. It may simply reflect differing roles of the GDP versus GTP bound forms in protein traffic. In this regard, the models that have been proposed to provide a general interpretation for rab protein function are likely to be oversimplified (Bourne, 1988). Clarification of these differences will require purification of the relevant proteins and characterization of their activities in vitro in the context of vesicular transport.

Mutations in the rabl and rab2 effector domains (Table 1, residues 32–40 [ras numbering]) were generated to disrupt the interaction with putative downstream effector molecules. Although effector domain mutations in YPT1 show a strong trans dominant phenotype (Becker et al., 1991) and a marked reduction in GTase stimulation by YPT1-GAP (Becker et al., 1991), identical mutations in rabl or rab2 only partially inhibited transport. Mouse rabla can substitute for yeast rabl in vitro (Schwaninger et al., 1992). However, the rapid recruitment of rabl coupled to the observation that the GDP-bound form of the SEC4 protein is required for membrane association (Kabpecell et al., 1990; Sasaki et al., 1991) suggests that the rablb121 mutant may inhibit transport by blocking the function of components involved in GDP/GTP exchange during an early step in vesicle formation. While the consequences of overexpression of the GDP-bound mutant form on cell morphology remain to be elucidated, an activated form, such as the rablb121 mutant may inhibit a later targeting or fusion step. This interpretation is supported by the observation that VSVG-G protein accumulates in punctate vesicular structures which are reminiscent of pre-Golgi intermediates (Saraste and Svensson, 1991) in the presence of mutant protein in vitro, and in the presence of the rab3AL peptide in vitro (Schwaninger et al., 1992). Moreover, it is consistent with the observation that similar activating mutations in SEC4 (Walworth et al., 1989) or YPT1 (Segev et al., 1988; Bacon et al., 1989; Baker et al., 1990; Kaiser and Schekman, 1990; Rexach and Schekman, 1991) result in the accumulation of intermediate

Role of rab Proteins in Vesicular Trafficking Between the ER and Golgi Compartments

The mutational analysis of rab protein function is consistent with a number of biochemical probes we have developed to explore rabl protein function in vitro. Recently we demonstrated that transport between the ER and the Golgi complex in vitro can be inhibited by a monoclonal antibody specific for rabl (Plutner et al., 1991). In the absence of rabl, VSVG-G protein fails to exit the ER suggesting that rabl or rablb-associated proteins are essential for vesicle formation (Plutner et al., 1992). Upon initiation of transport in vitro, VSVG-G protein becomes rapidly transported to pre-Golgi intermediates enriched in rabl (Plutner et al., 1992; Schwaninger et al., 1992). This rapid recruitment of rabl coupled to the observation that the GDP-bound form of the SEC4 protein is required for membrane association (Kabpecell et al., 1990; Sasaki et al., 1991) suggests that the rablb121 mutant may inhibit transport by blocking the function of components involved in GDP/GTP exchange during an early step in vesicle formation. While the consequences of overexpression of the GDP-bound mutant form on cell morphology remain to be elucidated, an activated form, such as the rablb121 mutant may inhibit a later targeting or fusion step. This interpretation is supported by the observation that VSVG-G protein accumulates in punctate vesicular structures which are reminiscent of pre-Golgi intermediates (Saraste and Svensson, 1991) in the presence of mutant protein in vitro, and in the presence of the rab3AL peptide in vitro (Schwaninger et al., 1992). Moreover, it is consistent with the observation that similar activating mutations in SEC4 (Walworth et al., 1989) or YPT1 (Segev et al., 1988; Bacon et al., 1989; Baker et al., 1990; Kaiser and Schekman, 1990; Rexach and Schekman, 1991) result in the accumulation of intermediate
transport vesicles in vivo and in vitro. The role of rab2 in transport is unknown. However, the observation that endo-
cytosis involves at least two rab proteins, rab4 and rab5 (Gorvel et al., 1991; van der Sluijs et al., 1991) suggests that multiple rab proteins may regulate sequential or competing biochemical interactions between intracellular compartments.

Through examination of the biochemical and morphological consequences of expression of these and additional mu-
tants on protein transport in vivo and in vitro we hope to gain insight into the role of rab and rab2 in ER to Golgi traffic.

We thank A. Tavitian, M. Zerial, J. Rose, C. Machamer and K. Nielsen (Stratagene Corp.) for providing reagents used in these studies. TSRI manuscript number 7457-CB.

This research was supported by grants from the National Institutes of Health to W. E. Balch (GM33301, GM42336, and CA27489) and C. L. Der (CA42978, CA52072, CA55008). E. L. Tisdale is a recipient of a Na-
thional Institutes of Health postdoctoral fellowship (CA 09270).

References

We thank A. Tavitian, M. Zerial, J. Rose, C. Machamer and K. Nielsen (Stratagene Corp.) for providing reagents used in these studies. TSRI manuscript number 7457-CB.

This research was supported by grants from the National Institutes of Health to W. E. Balch (GM33301, GM42336, and CA27489) and C. L. Der (CA42978, CA52072, CA55008). E. L. Tisdale is a recipient of a Na-
thional Institutes of Health postdoctoral fellowship (CA 09270).

We thank A. Tavitian, M. Zerial, J. Rose, C. Machamer and K. Nielsen (Stratagene Corp.) for providing reagents used in these studies. TSRI manuscript number 7457-CB.

This research was supported by grants from the National Institutes of Health to W. E. Balch (GM33301, GM42336, and CA27489) and C. L. Der (CA42978, CA52072, CA55008). E. L. Tisdale is a recipient of a Na-
thional Institutes of Health postdoctoral fellowship (CA 09270).

We thank A. Tavitian, M. Zerial, J. Rose, C. Machamer and K. Nielsen (Stratagene Corp.) for providing reagents used in these studies. TSRI manuscript number 7457-CB.

This research was supported by grants from the National Institutes of Health to W. E. Balch (GM33301, GM42336, and CA27489) and C. L. Der (CA42978, CA52072, CA55008). E. L. Tisdale is a recipient of a Na-


